Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 |
| NCT00412503 | Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents | completed | Phase 1 | — | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT01791478 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 1 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02223208 | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13) | completed | Phase 1 / Phase 2 | 89 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05036577 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL(ORMD2021) | completed | Phase 1 | 13 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05046171 | Decreasing Polypharmacy in Older Adults With Curable Cancers Trial | completed | Phase 1 / Phase 2 | 50 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05220046 | Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | completed | Phase 1 | 18 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06047184 | Phase I Study of BEBT-209 in Women With Advanced Breast Cancer | completed | Phase 1 | 100 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00720785 | Natural Killer Cells and Bortezomib to Treat Cancer | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01167530 | Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer(RAD001) | completed | Phase 1 | 26 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03650764 | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Washington University School of MedicineOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 61 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04942626 | Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients(ACO/ARO/AIO-21) | completed | Phase 1 | 12 | Goethe UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | completed | Phase 1 / Phase 2 | 33 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04858958 | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation(FAVOUR) | completed | Phase 1 | 90 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02217956 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma(CHIPASTIN) | completed | Phase 1 | 30 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02227199 | Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma(BV-ICE) | completed | Phase 1 / Phase 2 | 45 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02515877 | Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers(HPV-RX) | completed | Phase 1 | 15 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02732184 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | completed | Phase 1 | 21 | Immedica Pharma ABINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04447027 | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04522336 | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer | completed | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT06251050 | A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy | completed | Phase 1 / Phase 2 | 175 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02119858 | Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | completed | Phase 1 | 134 | AbbVieINDUSTRY | 7 | Aug 12, 2026 | clinicaltrials |
| NCT03440567 | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | completed | Phase 1 | 94 | Compugen LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06139211 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 66 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03495882 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | completed | Phase 1 / Phase 2 | 175 | Agenus Inc.INDUSTRY | 9 | Aug 11, 2026 | clinicaltrials |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 77 | AmgenINDUSTRY | 11 | Aug 11, 2026 | clinicaltrials |
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | completed | Phase 1 | 17 | NeoImmuneTechINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05262556 | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas | completed | Phase 1 | 15 | Amr Mohamed MDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04145349 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | completed | Phase 1 / Phase 2 | 30 | Eli Lilly and CompanyINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT02561234 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | completed | Phase 1 | 76 | Immedica Pharma ABINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer | completed | Phase 1 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04386967 | OH2 Injection in Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT00911560 | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | completed | Phase 1 / Phase 2 | 374 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 52 | Jennerex BiotherapeuticsINDUSTRY | 3 | Aug 5, 2026 | clinicaltrials |
| NCT06006403 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | completed | Phase 1 / Phase 2 | 5 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02211768 | Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 | completed | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04825288 | XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer(1-BETTER) | completed | Phase 1 / Phase 2 | 76 | XBiotech, Inc.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors(ABOYA-119) | completed | Phase 1 / Phase 2 | 43 | Aprea TherapeuticsINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05906537 | SKB410 for Injection in Solid Tumors | completed | Phase 1 | 38 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT01024231 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 127 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2026source: clinicaltrials